Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2020 September;66(3) > Minerva Gastroenterologica e Dietologica 2020 September;66(3):201-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Gastroenterologica e Dietologica 2020 September;66(3):201-7

DOI: 10.23736/S1121-421X.20.02662-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Fecal gluten immunogenic peptides as indicators of dietary compliance in celiac patients

Brunetta PORCELLI 1 , Fabio FERRETTI 2, Francesca CINCI 1, Ivano BIVIANO 3, Alessia SANTINI 3, Elisabetta GRANDE 4, Francesco QUAGLIARELLA 4, Lucia TERZUOLI 1, Maria R. BACARELLI 2, Nicola BIZZARO 5, Marina VASCOTTO 4, Mario MARINI 3

1 Section of Biochemistry, Department of Medical Biotechnologies, University of Siena, Siena, Italy; 2 Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy; 3 Unit of Gastroenterology and Operative Endoscopy, Siena University Hospital, Siena, Italy; 4 Unit of Pediatrics, Siena University Hospital, Siena, Italy; 5 Laboratory of Clinical Pathology, San Antonio Hospital Tolmezzo, Udine Integrated University Healthcare Company, Udine, Italy



BACKGROUND: It is important to have methods for evaluating dietary compliance in patients with celiac disease (CD). Determination of fecal gluten immunogenic peptides (GIPs) was recently proposed as a method of detecting gluten intake. The aim of this study was to evaluate whether determination of GIPs can be used as an indicator of compliance with a gluten-free diet (GFD).
METHODS: Twenty-five persons with CD on a gluten-free diet for at least one year were enrolled in the study. Compliance with the diet was assessed by the Biagi questionnaire, evaluation of symptoms and assay of IgA anti-tissue transglutaminase antibodies (IgA anti-tTG). GIPs were determined by iVYLISA GIP-S test (Biomedal S.L., Seville, Spain) on an automated Chorus analyzer (DIESSE Diagnostica Senese, Siena, Italy), after extraction of fecal samples by the method developed by DIESSE.
RESULTS: Four patients tested positive for GIPs (GIP+), two of whom complied strictly with the gluten-free diet according to the Biagi questionnaire. None of the four GIP-positive patients manifested symptoms. IgA anti-tTG was significantly higher in GIP+ than in GIP- subjects.
CONCLUSIONS: Assay of fecal GIPs identified more patients who were not complying with the diet than the Biagi questionnaire or evaluation of symptoms. The anti-tTG and GIP results agreed perfectly; however, since anti-tTG antibodies remain high for longer and are not a completely reliable marker of GFD intake, detection of fecal GIPs offers a direct, objective, quantitative assessment of exposure, even occasional, to gluten and could be used to check dietary compliance.


KEY WORDS: Diet, gluten-free; Celiac disease; Glutens

inizio pagina